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Section 1: HIV-1 Multidrug Resistant Protease with Residue 28 Insertion 
CHAPTER I: INTRODUCTION 
1.1 HIV-1 Viral Background 
 Human immunodeficiency virus (HIV) is a positive-sense, enveloped lentivirus that infects 
CD4+ T cells and can lead to the development of acquired immune deficiency syndrome (AIDS)	
[2]. 
1.2 Clinical Background 
 The Center for Disease Control (CDC) estimates that 1.2 million people are living with HIV in 
the United States as of 2013 and about 36.7 million people worldwide as of June 2016 (CDC, 
2016). HIV remains a worldwide concern as fatalities due to opportunistic infections continue to 
occur [3]. HIV is a retrovirus predominantly found as the HIV-1 strain [4, 5] . HIV-1 contains 
different viral proteins necessary for propagating its viral life cycle, one of which is the HIV-1 
protease [6-9] .  
1.3 Viral Mechanism/Protease Significance 
 HIV-1 protease (HIV-1 PR) is a 99 amino acid aspartyl protease that cleaves the Gag and Gag-
pol polyproteins in 9 locations to release mature proteins required for new virion assembly [6, 7, 
10-12]. The mechanism underlying the cleavage of the polyproteins is an almost symmetric 
interaction between the substrate and the catalytic aspartate residues from each monomer [13, 
14]. 
1.4 Mutations/Insertions 
 Inhibiting the HIV-1 PR with one of nine FDA-approved protease inhibitors (PI) has proven to 
be a successful strategy to prevent viral maturation; however, drug resistance mutations in HIV-1 
PR may act as a survival mechanism for the virus under pharmacologic pressure [15]. Multidrug 
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resistant mutations acquired by HIV-1 PR render conventional protease treatments less effective 
[12, 15-20], thus increasing the survival of the virus [12].  
 Insertion mutations are vastly underrepresented in the literature and their role remains unclear. 
We have recently identified a clinical isolate from the Wayne State University Infectious Disease 
Clinic in Detroit, MI which contains a five residue insertion between codons 28 and 29 of 
multidrug resistant HIV-1 protease. 
1.5 Specific Aim 
 To study the effects of the five residue insertion on HIV-1 PR function, we created a homology 
model of the insertion mutant and submitted the model to a 40 ns molecular dynamics 
simulation.  
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CHAPTER II: MATERIAL AND METHODS  
2.1 Phenotypic and Genotypic data 
 Phenotypic data for MDR28 was obtained by Phenosense® HIV drug resistance assay as 
performed at the Detroit Medical Center [21]. Genotypic data from the sequence of the mutant 
PR was provided by the Viroseq® HIV-1 genotyping system [22].  
2.2 Homology Modeling 
 A homology model of multidrug resistant HIV-1 PR (MDR) containing a five amino acid 
insertion, Asp-Asp-Thr-Ile-Leu (DDTIL), immediately to the c-terminal side of the 28th residue 
(MDR28) was created using SWISS-MODEL [23-26].  A wild-type (WT) HIV-1 PR crystal 
structure, 2O4S.pdb was obtained from the RCSB protein data bank and used as a template for 
the MDR28 homology model [27]. A homology model for MDR without the insertion was made 
using the same template (2O4S.pdb). The crystal structure 2O4S was used as a WT control. The 
resulting homology model for the MDR28 was a homodimer containing a total of 208 amino 
acids. The WT and MDR models each contained 198 amino acids. All of the models were 
subjected to 40ns molecular dynamics(MD) simulations. 
2.3 Molecular Dynamics Simulations  
2.3.1 Protease Complex Preparation 
 Visual Molecular Dynamics (VMD) software (VMD v.1.9.2) [27] was used to prepare the 
systems for MD simulations. WT, MDR, and MDR28 were prepared without a peptide (apo) 
resulting in three systems, respectively.  
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2.3.2 System Preparation 
 The preparation of the system for the MD simulation was carried out using VMD software 
(VMD v.1.9.2) [28]. The PR complexes as well as the apo structures were placed in a 12 Å 
TIP3P water box and were then neutralized with 0.15 M MgCl2. The simulations were performed 
for 40ns using NAMD (e) V 2.9. [29] and CHARMM force field 36 to set parameters [30] as 
previously described [31]. All simulations were run on the Wayne State University Grid 
(www.grid.wayne.edu). 
2.4 Analysis 
2.4.1 Structural Analysis  
All structural analysis was carried out using VMD (VMD v1.9.2) [28]. Frame 17,000 was 
selected as a model frame for WT, MDR, and MDR28 out of the 20,000 frame simulation. This 
frame was chosen as it is located further into the simulation after the proteases have had time to 
adjust and stabilize. 
RMSD values were calculated over the last 10 ns of the simulation using VMD (v 1.9.2). 
RMSF values were calculated for all 40 ns of the simulation. Secondary structural analysis was 
completed using the Ramachandran plot analysis tool. Ramachandran plots were used to analyze 
residues 23-42 of all three protease models for the last 10 ns of the simulation. RMSD model 
alignments of the full length PR, the hinge region, and the flap region were taken at 5 ns intervals 
of each PR RMSD. Model averages of MDR and MDR28 aligned with WT were also taken at 5 
ns intervals throughout the simulation using the RMSD alignment tool in the PyMOL Molecular 
Graphics System (Version 1.8 Schrödinger, LLC). 
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CHAPTER III: RESULTS 
3.1 Reduced replicative capacity and drug resistance of MDR28  
 In a Phenosense® susceptibility test, clinical isolate MDR28 displayed full or partial 
resistance to the following protease inhibitors (PIs): atazanavir (ATV/r), amprenavir (AMP/r), 
indinavir 
(IDV/r), 
tipranavir 
(TRV), and 
nelfinavir (NFV) 
(Table 1). 
Viroseq®, a 
genotypic 
antiretroviral drug 
resistance report 
was then 
performed, and 
MDR28 showed 
resistance 
mutations 
impacting the PIs IDV, LPV, 
fosamprenavir (FPV), and 
possible resistance to TPV, DRV, and ATV. Saquinavir (SQV) was the only inhibitor for which 
there were no known resistance mutations present (Table 1). A list of resistance mutations found 
Table	2.	MDR28	resistance	mutations	and	corresponding	PI	resistance.	
Summary	of	Viroseq®	HIV-1	genotype	report	with	possible	PI	resistance	
profile.	
Table	1.	Phenotypic	and	genotypic	susceptibility	data.	Summary	of	phenotypic	and	genotypic	resistance	
data	provided	by	Phenosense®	and	Viroseq®.	
	 	
	
6	
in MDR28, and their contributions 
are available in Tables 1 and 2. 
Genotypic reports are more 
predictive of future drug resistance, 
and the phenotypic data can be 
predictive of the clinical outcome. It 
was also determined in a 
Phenosense® replicative capacity assay 
that in the absence 
of inhibitors the 
isolate MDR28 
functioned at a 
reduced replicative 
capacity compared 
to WT (only 29% of 
WT) (Figure 1).  
 
3.2 Homology modeling of MDR28, WT, and MDR of MDR28, WT, and MDR: 
Wildtype (WT) HIV-1 PR is a 99 amino acid aspartyl-protease. Two 99 amino acid 
monomers form a homodimer to create active HIV-1 PR. [7, 8, 11, 12]. In dimer form, both WT 
and multidrug resistant HIV-1 PR (MDR) contain 198 amino acids. MDR and the corresponding 
Figure	2.	Sequence	alignment	MDR28,	WT,	and	MDR.	The	
absence	of	an	insertion	is	indicated	by	dashes	(-),	homology	
indicated	with	by	the	presence	of	an	asterisk	(*),	mutations	
denoted	by	a	colon	(:).			
Figure	1.	Replicative	Capacity.	Comparison	of	replicative	
capacity	as	percentage,	visualized	as	a	bar	graph.	MDR28	
represented	with	green,	WT	represented	with	blue.	
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homology model showed 6 mutations within each monomer sequence. These mutations are 
consistent in both MDR and our multidrug resistant HIV-1 PR (MDR28) isolate with an insertion 
immediately following the carboxyl terminus of amino acid 28. This added insertion results in a 
homodimer with 208 amino acids. (Figure 1) 
The 5 residue insertion in MDR28 appears to promote the formation of an alpha helix in 
the hinge region that is not present in WT or MDR (Figure 2).The hinge region of the proteases 
are composed of amino acids 34-42 [2] , which normally affect the flap region and subsequent 
conformational ability [2]. The flap region is composed of residues 43-59 [2] and is responsible 
(a)	
(c)	
(b)	
Figure	3.	Ribbon	representations	of	HIV-1	PR	structures.	(a)	WT	shown	in	magenta,	catalytic	
asp25	in	red	(b)	MDR28	shown	in	in	green,	multi-drug	mutations	in	orange,	asp25	in	red,	and	
insertion	residues	in	yellow.	(c)	MDR	shown	in	cyan	with	multidrug	resistant	mutations	in	
orange	and	asp25	in	red		
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for the proteases ability to take on an “open” or “closed” conformation, affecting its ability to 
bind to the substrate [11]. 
3.3 Secondary structure analysis  
 To determine whether the alpha helix in MDR28 was transient or present throughout the VMD 
simulation (VMD v.1.9.2) [28], the hinge regions of each model were analyzed with 
Ramachandran diagrams. Ramachandran diagrams plot phi vs. psi angles of the peptide linkages 
between amino acids, which compose the protease backbone [32]. Each data point represents one 
of 5,000 frames that were analyzed (materials and methods). Plots were generated of the 
insertion and the surrounding residues for each monomer (denoted as monomer A and monomer 
B) over the last 10 ns of the simulation. The MDR28 insertion residues were labeled 28a-28e 
(Figure 5). A change in secondary structure for MDR28 is consistent throughout the last 10ns of 
the simulation. Alpha helix formation is observed at residues 29-35 in MDR28, corresponding to 
residues 34-40 in WT and MDR (Figure 6). No comparable secondary structure changes were 
seen in WT or MDR. No additional deviations in secondary structure were seen in surrounding 
residues. (Figure 4, Figure 7). 
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3.3.1 Prior to insertion 
 
 
 
	Chain	P’	
	
	 23	 24	 25	 26	 27	 28	
MDR	28	
	 	 	 	 	 	
MDR	
	 	 	 	 	 	
WT	
	 	 	 	 	 	
	
Chain	P	
	
	 23	 24	 25	 26	 27	 28	
MDR	28	
	 	 	 	 	 	
MDR	
	 	 	 	 	 	
WT	
	 	 	 	 	 	
Figure	4.	Ramachandran	plots	prior	to	insertion.	MDR28,	MDR,	and	WT	
residues	23-28	shown	above.	No	obvious	structural	deviations	noted.		
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3.3.2 Insertion residues 
 
	
Chain	P	
	 29/28a	 30/28b	 31/28c	 32/28d	 33/28e	
MDR	28	
	 	 	 	 	
MDR	
	 	 	 	 	
WT	
	 	 	 	 	 	
Chain	P’	
	 29/28a	 30/28b	 31/28c	 32/28d	 33/28e	
MDR	28	
	 	 	 	 	
MDR	
	 	 	 	 	
WT	
	 	 	 	 	
Figure	5.	Ramachandran	plots	corresponding	to	insertion	
residues.	MDR	and	WT	residues	29-33,	and	MDR28	residues	28a-
28e	shown	above.	No	obvious	structural	differences	noted.	
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3.3.3 After insertion 
 
 
 
 
	
Chain	P	
	 34/29	 35/30	 36/31	 37/32	 38/33	 39/34	 40/35	
MDR	28	
	 	 	 	 	 	 	
MDR	
	 	 	 	 	 	 	
WT	
	 	 	 	 	 	 	
Monomer	A	
	
Chain	P’	
	 34/29	 35/30	 36/31	 37/32	 38/33	 39/34	 40/35	
MDR	28	
	 	 	 	 	 	 	
MDR	
	 	 	 	 	 	 	
WT	
	 	 	 	 	 	 	
Monomer	B	
Figure	6.	Ramachandran	plots	after	insertion.	WT	and	MDR	residues	34-40,	
and	MDR28	residues	29-35	shown	above.	Alpha	helix	formation	observed	in	
residues	31-35	of	MDR28	only.	
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Chain	P	
	 41/36	 42/37	 43/38	 44/39	 45/40	 46/41	 47/42	
MDR	28		
	
	 	 	 	 	 	 	
MDR	
	 	
	
WT	
	 	
	
Chain	P	
	 41/36	 42/37	 43/38	 44/39	 45/40	 46/41	 47/42	
MDR	28		
	
	 	 	 	 	 	 	
MDR	
	 	
	
WT	
	 	
Figure	7.	Ramachandran	plots	after	insertion.	MDR28,	MDR,	and	WT	
residues	following	insertion.	No	obvious	structural	changes	observed	
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3.4 Flexibility analysis through RMSF calculations  
 To determine if the addition of an alpha helix affected hinge and flap flexibility, RMSF was 
analyzed across the 40 ns simulation. The RMSF calculations were analyzed with VMD software 
(VMD v.1.9.2) [28]. Averages of the monomers of all three proteases— WT, MDR, and MDR28 
were visualized as graphs (Figure 8) and models (Figure 9). No obvious changes in flexibility 
were noted. RMSF values were visualized for the hinge (Figure 10) and flap residues (Figure 
11) to ensure no changes were seen. The RMSF analysis did not show substantial changes in 
flexibility between the proteases in any location. 
3.4.1 RMSF averages of monomers  
Figure	8.	RMSF	Averages	of	monomers.	a)	RMSF	Averages	represented	as	line	graph	with	
average	RMSF	vs	residue.	b)	RMSF	averages	for	all	residues	represented	by	bar	graph		
 (a)	  (b)	
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3.4.2 RMSF flexibility models  
 
3.4.3 RMSF averages hinge region 
 (c)	
 (a)	  (b)	
Figure	9.	RMSF	Represented	by	Model	
Highlighting.	Red	indicates	a	high	degree	
of	flexibility,	blue	indicates	low	degree	of	
flexibility.	a)	WT	b)	MDR	c)	MDR28	
Figure	10.	RMSF	Averages	Hinge	Residues.	a)	RMSF	hinge	residues	
represented	by	RMSF	vs	Residue	line	graph	b)	RMSF	hinge	residues	
visualized	as	bar	graph	
 (a)	  (b)	
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3.4.4 RMSF flap region 
 
3.5 RMSD analysis  
Due to the presence of an alpha helix throughout the 40 ns simulation in MDR28, the 
effect of this structure on the flap and hinge dynamics were examined. RMSD analysis was 
calculated using VMD (VMD V.1.9.2.) [25] to determine whether the alpha helix altered the 
atomic coordinates in MDR28 compared to WT and MDR structures. Averaged RMSD values of 
each protease were taken and represented as line and bar graphs (Figure 12). In the hinge region, 
a peak is present at residue 39 of MDR28 (Figure 13). This deviation is not observed in WT or 
MDR. The flap residues were visualized using the same graphing methods (Figure 14). 
Comparatively, the dynamics of the flap region appear altered as well.  
 
 
 (b)	
Figure	11.	RMSF	Averages	Flap	Residues.	a)	RMSF	flap	residues	
graphed	as	RMSF	vs	residue.	b)	RMSF	flap	residues	visualized	as	a	bar	
graph	
 
(a)	
 (a)	
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3.5.1 RMSD averages homodimers and monomers 
 
3.5.2 RMSD hinge region 
 
 
 
 (b)	
Figure	12.	RMSD	Averaged	Monomer	Values.	a)	Averaged	monomer	
values	represented	as	line	graph	(RMSD	vs	residue).	b)	Averaged	residues	
visualized	by	bar	graph	
 (a)	
 (a)	  (b)	
Figure	13.	Average	hinge	region	RMSD	values.	a)	RMSD	hinge	averages	for	WT	
(blue),	MDR	(red),	and	MDR28	(green)	represented	by	line	graph	(RMSD	vs	
residue	b)	Averaged	hinge	region	RMSD	represented	by	bar	graph	
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3.5.3 RMSD flap region 
 
 
 
 
 
3.6 RMSD model analysis at 5 ns intervals suggests increased structural similarity: 
To determine whether the dynamics information translated to similarities in structural 
alignment, RMSD values of MDR and MDR28 aligned with WT were taken at 5 ns intervals 
throughout the simulation. The model alignment values were measured using the RMSD 
alignment tool in the PyMOL Molecular Graphics System (Version 1.8 Schrödinger, LLC). The 
results suggest that over time MDR28 acts with increased structural similarity to WT. MDR28 
consistently showed higher average similarity to WT in all three datasets—full length PR 
(Figure 15), hinge region (Figure 16), and flap region (Figure 17). The data for MDR and 
MDR28 were visualized using line graphs representing RMSD compared to WT vs time. Data 
averages for each region were visualized using bar graphs. The largest deviation in structural 
similarity between MDR and MDR28 when compared to WT, was seen between the flap regions 
(Figure 17), where MDR28 continued to show the highest amount of similarity to WT. The flap 
 (a)	  (b)	
Figure	14.	Average	flap	region	RMSD	values.	a)	RMSD	flap	region	averages	
for	WT	(blue),	MDR	(red),	and	MDR28	(Green)	represented	by	line	graph	
(RMSD	vs	residue).	b)	Averaged	flap	region	RMSD	represented	by	bar	graph	
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region is imperative in accessibility to the active site, and subsequent substrate recognition and 
cleavage [33]. Furthermore, in previous studies mutant isolates were compared and those 
differing in only the insertions showed higher overall rates of replication [14]. MDR28 appears 
to compensate for MDR mutations by increasing structural similarity to WT. These results may 
indicate compensation to promote viral fitness as the underlying mechanism that promotes 
cleavage of the polyproteins. Subsequently, this would be dependent on proper structure and 
subsequent interactions between the substrate and the catalytic residue asp25 [13, 14]. 
3.6.1 RMSD full length model analysis:  
 
 
 
 
 
 
(b)	(a)	
Figure	15.	RMSD	Model	Alignment.	a)	RMSD	PR	alignments	at	5	ns	intervals	
visualized	by	line	graph	(RMSD	compared	to	WT	vs	Time).	b)	RMSD	Alignment	
PR	averages	visualized	as	bar	graph.	
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3.6.2 RMSD hinge region model analysis:  
 
 
3.6.3 RMSD flap region model analysis:  
 
 
 
 
 
Figure	16.	RMSD	Model	Alignment	Hinge	Region.	a)	RMSD	hinge	region	
alignments	at	5	ns	intervals	visualized	by	line	graph	(RMSD	compared	to	WT	vs	
Time).	b)	RMSD	Alignment	hinge	region	averages	visualized	as	bar	graph.	
(a)	 (b)	
Figure	17.	RMSD	Model	Alignment	Flap	Region.	a)	RMSD	flap	region	
alignments	at	5	ns	intervals	visualized	by	line	graph	(RMSD	compared	to	WT	vs	
Time).	b)	RMSD	Alignment	flap	region	averages	visualized	as	bar	graph.	
(b)	(a)	
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CHAPTER IV: CONCLUSION AND DISCUSSIONS 
4.1 Overview 
HIV is an incurable virus that accounts for many deaths in the US and worldwide as documented 
by the CDC (https://www.cdc.gov/hiv/basics/statistics.html). HIV often progresses to AIDS [6], 
which ultimately decreases lifespan via modes such as opportunistic infections [2]. HIV protease 
plays a crucial part in the viral life cycle [5, 6, 9-11] and without its ability to function the virus 
is incapable of completing replication [1, 33]. Though protease inhibitors have been effective in 
treating HIV infections [7, 9, 18, 34], HIV-1 PR has mutated as a potential means of preserving 
its viral life cycle [14]. Multidrug resistant HIV is caused by specific mutations [11, 35]. 
Additionally, strains of multidrug resistant HIV-1 are more difficult to treat [11, 14-19] 
potentially due to different intermolecular forces created by the changes in 6 key amino acids 
[36]. It has been suggested that insertions may compensate for resistance mutations, but little 
literature currently exists [14].  
4.2 Key Findings 
 The insertion found in our clinical isolate created a shift in the protease structure, due to the 
addition of an alpha helix to the hinge region. This altered hinge region appears to act as a 
compensatory mechanism, reestablishing structural similarities to WT, which are necessary for 
efficient cleavage of viral polyproteins [13, 14].  The structural change is a likely contributor to 
the proteases ability to adopt “open” and “closed” conformations, as the hinge region is 
implicated in making conformational changes [18] by controlling the movement of the flap 
regions [10]. The flap residues are responsible for accessibility to the active site and subsequent 
substrate recognition and cleavage [33]. The change in hinge structure and dynamics resulted in 
a change in flap dynamics. The similarity in RMSD flap values for WT and MDR28 serves as 
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evidence of compensation and structural restoration. The insertion itself may be, in part, due to 
polymerase slippage [34] creating the consequential five amino acid repeat seen within the 
isolate. However, it is reasonable to think that the MDR28 hinge alteration is a viral adaptation 
as a means of promoting structural restoration, replicative capacity, and consequential viral 
fitness.  
4.3 Concluding Remarks 
 Further studies will need to be conducted to decisively conclude the role of insertions in viral 
fitness. 
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Abstract 
Human immunodeficiency virus-1 (HIV-1) is a widespread, incurable retrovirus known to cause 
immunodeficiency and a shortened life span. Despite successful treatment methods, HIV-1 
frequently mutates, resulting in antiviral resistance. Many therapies target the HIV-1 protease 
(PR), which is responsible for cleaving the viral polyprotein essential for its life cycle. HIV-1 PR 
often evades treatment by way of mutations and less commonly through residue insertions. We 
have identified a clinical isolate with a five residue insertion between residues 28 and 29. 
Through molecular dynamics simulations we analyzed the protease protein structure and 
determined that the residue insertion created a change in the secondary structure of the hinge 
region of the viral protease. Elucidating the role of insertions could both aid in understanding 
viral mutations as well as the theoretical effect on patient treatment/outcome. 
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Section 2: Chikungunya nsP2 Protein Optimization, Purification, Expression and Drug 
Design 
CHAPTER I: INTRODUCTION  
1.1 Chikungunya Virus Background: 
 Chikungunya virus (CHIKV) is a +ssRNA arbovirus belonging to the Alphavius genus, and the 
Togavirdae family [35-50]. Chikungunya is considered a neglected tropical disease by the World 
Health Association (WHO, http://www.who.int/neglected_diseases/diseases/en/), but is becoming 
a growing concern as an emergent virus to non-tropical climates, resulting from climate change 
and its consequential global warming, creating an increase in temperatures around the world [50-
56]. As an emerging virus, CHIKV may be most notable for severe arthralgia in infected patients 
spanning from days to years	[35-39, 41, 44, 45, 47, 49, 50, 57]. The pain is notoriously agonizing.  
The name “Chikungunya” is derived from the Makonde language meaning, “that which bends up” 
which serves as a descriptor of the contorted stance those plagued by severe arthralgia secondary 
to CHIKV infection exemplify [49, 55, 56, 58]. CHIKV was first identified in East Africa during 
the 1950s Tanzania outbreak [35, 37, 46, 49, 55, 59], but now affects a minimum of 45 countries 
spanning the Caribbean, and the Americas [39, 40, 51, 54, 55, 57, 58, 60]. The ability for CHIKV 
to span many countries is partially due to its mosquito vector. Its spread is additionally due to its 
capacity to mutate as an RNA virus [35, 40, 49, 59-62]. Originally, vectored by the mosquito Aedes 
aegypti, a mutation created the ability for a second, more aggressive mosquito Aedes albopictus to 
vector and spread the virus [35, 37, 39, 40, 45-47, 49, 52-56, 58, 60-63, 64]. As the climate 
continues to change, and mutations continue to occur, CHIKV will likely have the capability to 
continually adapt and spread to new locations. Subsequently, a good understanding of the virus 
and the viral life cycle is imperative. Furthermore, no FDA drugs are currently approved for the 
	 	
	
24	
treatment of CHIKV which garners a need for development of drug therapies and vaccines to 
prevent the spread of the disease to previously unaffected areas.  
 1.1.1 Cause: 
 CHIKV is caused by a mosquito vectored +ssRNA arbovirus [38, 41, 49, 50, 55, 56, 64]. It is a 
zoonotic virus, passed between humans and non-human primates via mosquito bite [39, 40, 45, 
46]. As an RNA virus CHIKV does not have proof-reading capabilities, making it adaptable by 
way of mutations [62]. Because of its small genome, one point mutation can make a substantial 
difference in transmission/vector compatibility [35, 40, 49, 59-62].  
 
 1.1.2 Viral Mechanism/Protease Significance:  
 The CHIKV genome is comprised of two open reading frames—one responsible for encoding 
the nonstructural protein precursor polyprotein, and the second for the encoding of the precursor 
polyprotein responsible for the three structural proteins [39, 45, 50]. There are four nonstructural 
proteins: nsp1, nsp2, nsp3, and nsp4 [39, 41, 45, 48]. Structural proteins are responsible for 
CHIKV viral enzymatic activities. The structural proteins are C (capsid), E1, and E2 (envelope 
proteins) [39, 41, 45, 48]. These are responsible for non-enzymatic, protective components of the 
virus. The nonstructural polyprotein is P1234, which is self-cleaved by the protease activity of 
nsP2 [41, 44-46, 48-50]. The nonstructural proteins, after cleavage, form a replication complex 
responsible for viral replication [41, 44-46, 48-50, 63]. Each nonstructural protein plays an 
important role. Nsp1 plays a functional role in attaching the replication complex to the cell 
membrane, thus acting as an anchor for the complex [41, 45]. Nsp2 has dual roles—cleaving 
imperative viral nonstructural proteins of the replication complex with its protease and helicase 
activity. Additionally, the nsp2 plays an active role in evading the host innate immune system by 
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means of activating the transcription-coupled repair mechanism in the host cell. This repair 
mechanism destroys polymerase II catalytic subunit, Rbp1, by ubiquitination and degradation. 
This mechanism also suppresses JAK-STAT signaling pathway in the host cell —both of which 
are necessary for viral propagation and survival in the host. Additionally, nsp2 has nucleoside 
triphosphatase (NTPase) and RNA-dependent 5-triphosphatase capabilities [41, 44-49, 63]. Nsp3 
functions as cofactor for nsp4 [41] and also acts as part of the replication complex. Aside from 
its involvement as a cofactor, the function of nsp3 is not fully understood [45]. Lastly, nsp4 is the 
RNA-dependent RNA polymerase responsible for replication [41, 45, 49]. Because of its 
essential role in both evasion of the immune system and viral life cycle, nsp2 has been 
recognized as a promising pharmaceutical target [44-48, 63].  
 
1.2 Clinical Background 
 1.2.1 Impact/Demographic: 
 CHIKV was initially isolated in the early 1950s in Tanzania and northern Mozambique [35, 37, 
46, 49, 55, 59]. At first it was thought to be a self-limiting tropical virus; however, it has been 
reported to result in severe complications and fatalities [60, 61]. Throughout the last several 
decades, CHIKV has continued to spread to new, unaffected regions and is now found in at least 
45 countries [39, 40, 51, 57, 58, 60]. Presently, outbreaks cease to be contained to tropical 
climates. The ability to infect other climates may increase due in part to mutations and infected 
travelers, as well as climate change potentially influencing the vectors [37, 47, 50, 53, 55]. 
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 1.2.2 Symptoms: 
 CHIKV is characteristically known for the symptom of extreme arthralgia, which can be either 
acute or chronic [35-39, 41, 44, 45, 47, 49-51, 53, 56, 57, 65]. The name of the CHIKV came 
from the notorious, severe arthralgia it is known for. Its name means “that which bends up,” 
which describes the contorted posture of an infected patient [49, 55, 56, 58]. The joint pain can 
be debilitating and has the ability to progress into deforming arthritis [66]. Additionally, chronic 
arthralgia can occur which can span for over a year post infection [57]. Chronic patients may 
exhibit high levels of interleukin 6, as well as high levels of granulocyte macrophage colony-
stimulating factor without the normal increase in TNF or IL-1b characteristic of other forms of 
inflammation triggered arthritis [61]. With the ongoing threat of spread due to increases in 
globalized travel, global warming, and viral mutations facilitating adaption to new vectors [37, 
47, 50, 53, 55], rheumatologists are likely to face challenging and unexpected cases of arthralgia 
due to CHIKV as the virus migrates to more temperate, northern climates.  
 Normally symptoms are acute in nature, lasting from 3-10 days [50, 57]. Other symptoms 
associated with CHIKV include an acute onset of high fever, nausea, vomiting, maculopapular 
rash, myalgia, headache, and chills [35, 36, 39, 41, 44-47, 50, 53-56, 58, 64]. CHIKV patients 
presenting with Guillain-Barre syndrome and associated neurological symptoms have been 
reported [67]. Guillain-Barre syndrome is a rare condition, which can progress to troubling 
symptoms such as flaccid quadriparesis and decreased swallowing and/or breathing capability 
[67]. Although these symptoms are normally reversible, fatalities can occur due to 
complications. Initially CHIKV was thought to be a self-limiting illness [39, 51, 53, 61], 
however, its spread in Reunion Island resulted in 254 reported deaths related either directly or 
indirectly to CHIKV [61]. With the potential emergence of CHIKV to previously unaffected 
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areas it is important that medical professionals are prepared to diagnose and treat the condition 
efficiently. Quick treatment may decrease the likelihood of chronic and debilitating symptoms 
such as neurological complications, or even death. 
 
 1.2.3 Treatment/Prognosis: 
 No known FDA approved antivirals currently exist [68], although, a recent study conducted a 
drug screen with potential for berberine, abamectin, and ivermectin (used as anti-insect or anti-
parasitic agents, with the potential for wide-spectrum antiviral use).  These three agents showed a 
reduction in viral RNA synthesis, although the mechanism of action is not fully understood [38]. 
Currently, treatments are focused on alleviating symptoms and inflammation. 
 
1.3 Global Warming and Drug Design Urgency  
 1.3.1 Global Warming Predictions: 
 Over the past several decades, atmospheric changes have resulted from an increase in 
greenhouse gases. Gasses indicated in the atmospheric changes include carbon dioxide, methane, 
and nitrous oxide	[69]. The increase of gasses due to manmade activity, such as fossil fuel 
combustion, has led to a warming of the earth’s surface. [69, 70]. This increase in temperature 
may facilitate an increase in diseases	[69-71]. Viruses vectored by mosquitos, such as CHIKV, 
present a threat of emergence with climate change as their vectors have the potential to carry out 
their life cycle in new areas, due to the increased heat, moisture, deforestation, and other 
ecological changes [55, 69-71]. CHIKV presents a substantial threat of complications to northern 
climates with naïve populations, who are largely unexposed to the virus	[64]. Unaffected 
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populations have the potential to quickly spread the virus, suffer severe complications, and even 
potential fatalities, due to exposure [60].  
 
 1.3.2 Vectors and Distribution: 
 CHIKV is primarily vectored by the Aedes aegypti and Aedes albopictus mosquitos [52-56, 58, 
60, 61, 64]. CHIKV underwent a mutation first discovered in the 2006 La Reunion viral 
outbreak, which created the ability for Aedes albopictus to act as a vector [60,	61].	Aedes 
albopictus is capable of spreading the virus to a larger geographical range, due to its ability to 
survive variable conditions—both rural and urban [52, 55 , 56, 58, 60, 61, 64]. Climate 
predictions yielded varying results on the outcome for CHIKV vectors due to climate change 
[72-83]. Although vector predictions vary, it is essential to be prepared as climate change 
escalates. Furthermore, it is imperative that effective antiviral therapy is available to combat the 
potential emergence of CHIKV and other vectored viruses in new geographic locations with 
unaffected, at-risk populations.  
 
1.4 Specific Aims: 
 The goal of this research is to optimize, express, and purify CHIKV nsP2 protease, with the 
future direction of small molecule drug design to inhibit nsP2.  
 
1.5 Significance:  
 Currently there are no known FDA approved CHIKV treatments. CHIKV outbreak is treated by 
alleviating symptoms, as no known, effective antiviral exists. With the threat of Arboviral 
emergence to unaffected areas of the world, pharmaceutical treatments are imperative. 
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CHAPTER II: MATERIALS AND METHODS  
2.1 Cloning and Small Scale Expression: 
 Chikungunya virus nsp2 protease (CHIKV) was cloned into a SUMO vector at EZbiolab, inc. 
(EZBioLab, 2015). A fusion protein was made with a 6x His attached to a SUMO tag, followed 
by the nsp2 CHIKV sequence with an Ampicillin resistance gene. The clone was transformed 
into Escherichia coli BL21 Codon Plus (DE3) cells for protein expression.  
 Protein expression optimization was preformed using 5 mL, small scale cultures. The SUMO 
tagged CHIKV protein was grown in 5 mL LB medium in the presence of Ampicillin. Protein 
expression was induced by addition of isopropyl-β-D-thiogalactoside (IPTG). To optimize 
protein overexpression the following variables were tested: optical density(OD600) prior to 
induction, IPTG concentration, and temperature. Induction of the cell cultures was carried out at 
OD600 0.5 or 1.0 with the addition of IPTG at the following concentrations: 0.1mM, 0.5mM, or 
1.0mM. Following IPTG induction of the cell culture, protein expression was carried out at 
either 37°C for three hours or 15°C overnight. After the incubation period the cells were lysed 
using lysozyme and polyacrylamide gel electrophoresis(SDS-PAGE) (15% w/v polyacrylamide) 
was used to determine protein expression levels and solubility (Figure 18). Results of 
optimization summarized in Figure 19.  
	 	
	
30	
 
Temp:	37	⁰C	
[IPTG]:	0.5mM	
0.5	OD600	 1.0	OD600	
66.4	kDa	
55.6	kDa	
27.0	kDa	
Temp:	37	⁰C	
OD600:	1.0		
1.0	mM	IPTG	
0.1	mM	IPTG	 0.5	mM	IPTG	
66.4	kDa	
55.6	kDa	
27.0	kDa	
Figure	18.	Nsp2	Optimization.		
Protein	optimization	of	CHIKV	
nsp2.	First	gel	(top)	tested	the	
OD600	condition.	Second	set	
of	gels	(middle)	tested	IPTG	
concentration.	The	third	set	of	
gels	(bottom)	tested	
temperature.	Constant	
conditions	are	listed	and	
boxed	to	the	left	of	the	
corresponding	SDS-PAGE	gel.		
Temp:	15	⁰C		
66.4	kDa	
55.6	kDa	
27.0	kDa	
Temp:	37	⁰C		
66.4	kDa	
55.6	kDa	
27.0	kDa	
[IPTG]:	0.5mM	
OD:	1.0	
Figure	19.	Optimization	Results.	Summary	
of	optimization	results	for	nsp2.	
Optimization	showed	the	best	
temperature	is	15°C,	IPTG	concentration	
as	0.5mM,	and	the	best	OD600	as	1.0.			
[IPTG]	
0.1	mM	 15°C	 0.5	
Temp.	 OD
600
	
0.5	mM	 37°C	 1.0	
1.0	mM	
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2.2 Large Scale Protein Expression and Purification:  
 Large scale protein expression was attained using 2 liter cultures. The optimized condition for 
growth of the cultures was as follows: induction with 0.5mM concentration of IPTG, OD600 of 
1.0, expression at 15°C overnight. The following day the cells were harvested via centrifugation 
and lysed by French Press. A Ni2+ affinity column (HisTrap™ HP, GE) was used to purify the 
soluble fraction. The SUMO tag was separated from CHIKV by proteolytic cleavage of the His6-
SUMO tag with yeast SUMO Protease 1 after the elution of the fractions. The cleaved protein 
was subjected to an additional round of Ni2+ purification followed by size-exclusion 
chromatography (Superdex 200, GE). Purified CHIKV was collected and concentrated to ~19 
mg/mL. The accuracy of the purified protein in the elution fractions were tested using SDS-
PAGE (15% w/v polyacrylamide). The gels were used to analyze the filtrate based on size and 
Coomassie Brilliant Blue staining was used to visualize the protein bands. 
 
2.3 Characterization of Enzyme Activity   
 FRET-based fluorometric enzyme assay was used to test the enzymatic activity of CHIKV. 
CHIKV was diluted in reaction buffer containing Tris 50mM, NaCl 10mM, at a pH of 9.1 to a 
final concentration of 539 nM. The reaction was initiated by adding FRET substrate (AnaSpec 
Inc.). The substrate used is based on the P4-P5’ residues of the nsp1/nsp2 (residues 
RAGAGIEK), nsp2/nsp3 (RAGCAPSYK), and nsp3/nsp4 (RAGGYIFSK) cleavage sites. The 
FRET substrate was serially diluted from concentrations of 100 µM to 39 nM and 75µM to 
37.5µM then added to the reaction to determine the kinetic parameters. The final reaction 
volume within the well was 100 µL. A microplate reader (SpectraMax M5, Molecular Devices, 
Sunnyvale, CA, USA) was responsible for monitoring the fluorescence emitted by substrate 
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cleavage at 488 nm excitation wavelength with an emission wavelength of 520 nm. The reaction 
was performed at 37°C with readings taken every minute for a total duration of 21 minutes. 
Standard curves were created, data was plotted and analyzed using GraphPad Prism v. 6.07. 
 
 
CHAPTER III: RESULTS  
 3.1 Overexpression and Purification of CHIKV 
Protease: 
 Using the optimized overexpression conditions 
outlined in section 2.1, a 2 liter culture of E. coli 
was used to overexpress CHIKV. The resulting 
cells were collected via centrifugation and 
lysed by French press, Figure 20 [1]shows a 
flowchart representing the order in which 
purification occurred. Expressed SUMO-
CHIKV fusion protein is seen at ~ 55.6 kDa 
molecular weight on a 15% v/w polyacrylamide SDS-PAGE gel as shown in Figure 21. The first 
Ni2+ column was applied with the elution of SUMO-CHIKV protein as a result of an imidazole 
gradient. Figure 21 shows the results from the first Ni2+ column as well as the desalting column, 
visualized on SDS-PAGE. The elution fractions B1-B6 were cleaved by yeast SUMO protease to 
remove the SUMO tag from CHIKV prior to the second Ni 2+purification. CHIKV was eluted 
from second a Ni2+ column as seen in Figure 22. Partial ULP cleavage was observed, and SDS-
Ni
2+
	A
ffi
ni
ty
	
Cell	lysate	
(soluble	fraction)	
Ni
2+
	A
ffi
ni
ty
	
Si
ze
	E
xc
lu
sio
n	
ULP-1		
cleavage	
2.		
3.		 4.		1.		
Figure	20.	Protein	Purification	Scheme	[1].	
Purification	was	accomplished	through	two	Ni2+	
affinity	columns	(with	ULP-1	cleavage	of	SUMO	
between),	and	subsequent	Size	Exclusion	
chromatography.		
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55.6	kDa	
27.0	kDa	
66.4	kDa	
42.4	kDa	
34.6	kDa	
PAGE showed three protein bands.  
CHIKV is expected to present with the 
molecular weight of 37.4kDa, but bands 
were displayed at the experimental 
molecular weight of ~55.6kDa, ~35kDa, 
and ~19kDa on SDS-PAGE gel as seen in 
figure D. These results indicate partial 
ULP-1 cleavage, resulting in fusion 
protein, nsp2, and SUMO protein, 
respectively.  
 A final round of purification was 
obtained using size-exclusion 
chromatography. A strong, symmetrical 
peek is seen at ~86 mL indicting the 
beginning of CHIKV elution. The 
symmetrical peak indicates successful 
protein purification representative of only 
one species (Figure 23). Fractions D3-
D12 were concentrated to ~19mg/mL. 
 
 
 
 
66.4	kDa	
27.0	kDa	
34.6	kDa	
42.4	kDa	
55.6	kDa	
66.4	kDa	
27.0	kDa	
55.6	kDa	
34.6	kDa	
42.4	kDa	
Figure	21.	Optimization,	First	Nickel	Column,	and	
Desalting	Column.	(Top)	SDS-PAGE	gel	containing	the	
following:	lane	1:	marker;	lane	2:	induced;	lane	3:	
uninduced;	lane	4:	total,	lane	5:	supernatant;	lane	6	&	7:	
fractions	after	first	Ni2+	column;	Lanes	8	&	9:	before/after	
ULP	cleavage;	lane	10:	desalt	column.		Protein	is	soluble,	
but	incomplete	ULP	cleavage	is	observed.	(Bottom)	SDS-
PAGE	gel	containing	the	following:	lane	1:	marker;	lanes	2-
7:	1st	Ni2+	column	elution	fractions;	lanes	8-10	blank.		
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3.2 Characterization of 
Enzyme Activity   
FRET based assays were 
used to test enzymatic 
activity of purified CHIKV 
as described in section 2.3. 
Each substrate was tested to 
determine enzyme activity in 
the presence and absence of 
DTT in relation to the 
following cleavage sites 
(residues P4-P5’): nsp1/nsp2, 
nsp2/nsp3, and nsp3/nsp4. 
Each peptide contained a 
fluorescent tag (Hilyte Fluor 
TM, AnaSpec, Inc.) on the N-
terminus of the P4 Arginine.  
The enzyme optimization data is 
shown in Figure 24 as relative 
fluorescent units (RFU) as a 
function of enzyme 
66.4	kDa	
55.6	kDa	
27.0	kDa	
34.6	kDa	
42.4	kDa	
Figure	23.	Size-exclusion	Elution.	Results	for	the	size	exclusion	
elution.	The	sample	shows	a	symmetric	peak	(top)	when	
measuring	the	absorbance	vs	mL	of	sample,	and	one	protein	band	
(bottom)	in	SDS-PAGE	gel,	indicating	successful	purification	of	
CHIKV	nsp2.	The	lanes	of	the	SDS-PAGE	are	as	follows:	lane	1:	
marker;	lane	2:	gel	load;	lanes	3-10:	size-exclusion	elution	
fractions.		
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concentration. The nsp1/nsp2 
cleavage site showed the highest 
RFU (~0.3 RFU) without DTT at 
~256nM enzyme concentration. 
The nsp2/nsp3 cleavage site 
showed similar RFU values with 
and without DTT. The highest 
nsp2/nsp3 RFU (~0.25) was seen 
with DTT at ~512nM enzyme 
concentration. The nsp3/nsp4 did 
not show activity.  
 
 
CHAPTER IV: 
CONCLUSIONS AND 
DISCUSSIONS  
4.1 Overview: 
Expression, purification, and 
characterization of CHIKV was 
successful, yielding ~19 mg/mL or purified 
protein. The kinetic assays confirmed 
activity of CHIKV nsp2, further studies will 
Figure	24.	Enzyme	Activity	Assay.	Enzyme	
optimization	assay	results	measured	as	a	
function	of	RFU	as	a	function	of	enzyme	
concentration.	Results	recorded	without	
(top)	and	with	(bottom)	DTT.		
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aim at elucidating accurate binding information, as well as small molecule drug design.  
 
4.2 Key Findings: 
CHIKV appears to have an affinity for the gels used in purification. It is possible that this is due 
to ribose binding, as nsp2 is involved in the formation of the replication complex, and due to its 
NTPase activity, which provides energy for its helicase activity [41]. Additionally, when 
optimizing the protein, we found that it expresses best at lower temperatures (15 ⁰C). This may 
be in part due to its association with the replication complex docked to the cytosolic cell 
membrane [41]. The kinetic assays show enzymatic activity, creating the potential to test drug 
targets with nsp2, active protease.  
 
4.3 Concluding Remarks: 
In summary, we successfully optimized, expressed, and purified CHIKV nsp2 and conducted 
enzyme characterization assays which validated the enzymes activity. No FDA approved 
treatments currently exist for CHIKV, but with the threat of an Arborviral migration to 
previously unaffected climates due to global warming and other globalization factors, drug 
design to inhibit fundamental portions of the viral cycle is imperative. Future studies will aim to 
conduct drug screens and to crystalize wildtype CHIKV to yield accurate results for potential 
small molecule protease inhibitors.   
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Abstract: 
Chikungunya virus (CHIKV) is an incurable Arbovirus creating the most notable symptom of 
severe and sometimes chronic arthralgia. CHIKV is considered a neglected tropical virus by the 
World Health Association (WHO), with the potential of becoming a larger scale threat in part 
due to the influence of global warming on the mosquito population that serve as vectors for 
CHIKV. The virus has a life cycle is dependent on its nonstructural protein function, one of 
specific interest is nsP2. We have successfully expressed, optimized, and purified active CHIKV 
nsP2. Future studies will look at small peptidomimetic drug design.   
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